Dr. Sven Rihm

Counsel

ミュンヘン + 49.89.20.60.42.200

Connect:

共有

Dr. Sven Rihm is a German and European patent lawyer who has been advising clients for almost 25 years on all aspects of intellectual property law. In addition to decades of experience in obtaining and securing intellectual property rights, he has extensive practical experience in opposition, appeal, and nullity proceedings before the German and European Patent Offices, the Federal Patent Court, and the Unified Patent Court. Sven also advises on matters relating to supplementary protection certificates (SPCs) and prepares freedom-to-operate and due diligence analyses, as well as patent validity opinions.

His academic background enables him to advise clients on all technical aspects in the fields of organic, inorganic, and technical chemistry, as well as on technologies in the fields of life sciences, biotechnology, and pharmaceuticals.

Prior to joining Jones Day, Sven practiced at one of Germany's largest law firms and at a small German IP boutique.

Sven is a member of the German Patent Lawyer's Association (PAK), the Institute of Professional Representatives before the European Patent Office (epi), the International Federation of Industrial Property Attorneys (FICPI), and the Association of Intellectual Property Experts (VPP).

担当案件

  • LyondellBasell acquires APKJones Day advised LyondellBasell in the acquisition of APK AG in Merseburg, Germany.
  • Vibrantz moves to invalidate sinter paste patent before Unified Patent Court in MunichJones Day represents Vibrantz GmbH, a manufacturer of specialty chemicals and materials, in patent invalidation counterclaim proceedings before the Unified Patent Court, Munich local division, in a dispute over certain precious metal sinter pastes for chip bonding.
  • Vibrantz defends patent dispute before Unified Patent Court in MunichJones Day represents Vibrantz GmbH, a manufacturer of specialty chemicals and materials, in patent litigation before the Unified Patent Court, Munich local division, in a dispute over certain precious metal sinter pastes for chip bonding.
  • Idenix enforces patent against Gilead in Germany over sofosbuvirJones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in Landgericht Düsseldorf in Germany over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
  • Idenix defends nucleoside analogue patent in EPO opposition against five opponentsJones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs.
  • Milliken & Company acquires Zebra-chemJones Day advised Milliken & Company in its acquisition of Zebra-chem GmbH, a global chemicals company known for its peroxide and blowing agent masterbatches.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Global manufacturer of specialty adhesives enforces hotmelt adhesive patent against major German competitorJones Day represents a manufacturer of specialty adhesives in patent litigation against a major German competitor before the courts in Düsseldorf and the German Federal Patent Court.
    •

    October 2022 Alert

    The Days are Numbered for the EPO's 10-Day Rule

    April 2020 Alert

    COVID-19 Accelerates Digital Transformation at the European Patent Office

    March 2017 Commentary

    Antidote to Toxic Divisionals—European Patent Office Rules on Partial Priorities

    June 2015 Alert

    The EPO's Undisclosed Disclaimers Trap—A Possible Way Out

    送信する前の注意事項：

    www.jonesday.comに掲載されている情報は、一般的な使用を目的としており、法的アドバイスを目的としたものではありません。このEmailを送信することにより、弁護士を含む専門家・依頼者の関係を構築することを意図するものではなく、このEmailの受領はそのような関係を構築するものではありません。当事務所に送信されたいかなる情報も、業務委託契約を結ばない限り、弁護士等が依頼者に対して守秘義務を負う機密事項として取り扱われることはありません。このEmailの送信者は以上の注意事項の内容を読み、理解したものと判断します。